Business
CapsoVision Reports First Quarter 2026 Financial Results
SARATOGA, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results for its first quarter ended March 31, 2026. Recent Highlights Delivered first quarter revenue of $2.8 million, stable compared to the first quarter of 2025.Existing customers continued to expand clinical use of CapsoCam Plus® for small bowel disease detection, while
About this update from Capsovision, Inc.
[{"type":"image","alt":"CapsoVision","displaySize":"","headline":null,"caption":"CapsoVision","className":"","disableSlideshowImg":false,"size":{"original":{"width":289,"height":82,"url":"https://media.zenfs.com/en/globenewswire.com/7997fdcf01bc3e4679fd070889da0319"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/SIaZW6hQ7uLjpz9n25nq0w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExOQ--/https://media.zenfs.com/en/globenewswire.com/7997fdcf01bc3e4679fd070889da0319","width":289,"height":82},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/SIaZW6hQ7uLjpz9n25nq0w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExOQ--/https://media.zenfs.com/en/globenewswire.com/7997fdcf01bc3e4679fd070889da0319","width":289,"height":82}},"lazy":false},{"type":"text","content":"SARATOGA, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results for its first quarter ended March 31, 2026.","length":277,"tagName":"p"},{"type":"text","content":"Recent Highlights","length":17,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Delivered first quarter revenue of $2.8 million, stable compared to the first quarter of 2025.","length":94,"tagName":"p"}]},{"val":[{"type":"text","content":"Existing customers continued to expand clinical use of CapsoCam Plus® for small bowel disease detection, while procedure volume demonstrated growing adoption and end-user consumption.","length":183,"tagName":"p"}]},{"val":[{"type":"text","content":"Secured key customer renewals with large GI networks, including Indiana University Health Systems, Providence Health Systems, and Gastro Health, reinforcing platform value and long-term relationships.","length":200,"tagName":"p"}]},{"val":[{"type":"text","content":"CapsoCam Plus® used by over 167,000 patients as of March 31, 2026.","length":66,"tagName":"p"}]},{"val":[{"type":"text","content":"CapsoVision’s AI-assisted reading feature for CapsoCam Plus, on track for anticipated FDA clearance mid-year, with commercial launch expected shortly thereafter, subject to FDA review timelines.","length":194,"tagName":"p"}]},{"val":[{"type":"text","content":"Pipeline programs progressing as planned, including our second-generation of CapsoCam Colon with 510(k) submission expected in the third qua...